This summary was created by AI, based on 8 opinions in the last 12 months.
Experts are generally positive about Vertex Pharmaceuticals Inc. and its potential for growth. The company's non-addictive painkillers and cystic fibrosis franchise are seen as strong points, with multiple experts expressing confidence in the stock's performance. Some caution is advised due to the stock's high valuation and the fact that much of the good news may already be reflected in the stock price.
Negative free cash flow to enter 2024, but it's turning positive. Shares are up 21% this year.
Even at this all time high don't sell. They're working on non-addictive painkillers
It's doing well, hitting new highs today. It's further along in its life cycle. Has a fine cystic fibrosis franchise. Shares are strong momentum, so he's staying in.
This drugmaker has a lock on MS and have new shots on pain management and other maladies. Lots going on. Up sharply this month.
Likes it, but she trimmed it because a lot of the good news from its pain medicine is now in the stock.
PPH, an ETF for pharma producers, is breaking out and near a record. VTX and Eli Lilly are leaders in this space and Vertex has a great product for Cystic Fibrosis therapeutics. It is growing well and not too expensive.
They're in the MS business, so will they expand beyond MS? HE's confident they will and have some hit drugs.
A high-quality biopharma with a strong cystic fibrosis drug. Are trying to get into other franchises like diabetes treatments. Will do well long-run. Trades at 23x with 11% earnings growth, so you can take some profits now. Had a good run, so take some money off the table.
Not too expensive. They report next week. They have good momentum and products.
Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX-Q on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX-Q
In the last year, 8 stock analysts published opinions about VRTX-Q. 5 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..
Vertex Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
8 stock analysts on Stockchase covered Vertex Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.
On 2024-12-12, Vertex Pharmaceuticals Inc. (VRTX-Q) stock closed at a price of $463.71.
Their anti-pain drug is not addictive and it works. He's a believer.